CA2315256A1 - Needle-free injection of formulated nucleic acid molecules - Google Patents

Needle-free injection of formulated nucleic acid molecules Download PDF

Info

Publication number
CA2315256A1
CA2315256A1 CA002315256A CA2315256A CA2315256A1 CA 2315256 A1 CA2315256 A1 CA 2315256A1 CA 002315256 A CA002315256 A CA 002315256A CA 2315256 A CA2315256 A CA 2315256A CA 2315256 A1 CA2315256 A1 CA 2315256A1
Authority
CA
Canada
Prior art keywords
needle
nucleic acid
delivering
acid molecule
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002315256A
Other languages
English (en)
French (fr)
Inventor
Lou Smith
Russ Mumper
Michael Barry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Urigen Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2315256A1 publication Critical patent/CA2315256A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA002315256A 1997-12-16 1998-12-16 Needle-free injection of formulated nucleic acid molecules Abandoned CA2315256A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6975497P 1997-12-16 1997-12-16
US60/069,754 1997-12-16
PCT/US1998/026823 WO1999031262A2 (en) 1997-12-16 1998-12-16 Needle-free injection of formulated nucleic acid molecules

Publications (1)

Publication Number Publication Date
CA2315256A1 true CA2315256A1 (en) 1999-06-24

Family

ID=22091009

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002315256A Abandoned CA2315256A1 (en) 1997-12-16 1998-12-16 Needle-free injection of formulated nucleic acid molecules

Country Status (5)

Country Link
EP (1) EP1038016A2 (de)
JP (1) JP2003528024A (de)
AU (1) AU1922999A (de)
CA (1) CA2315256A1 (de)
WO (1) WO1999031262A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
KR100750695B1 (ko) * 1999-07-20 2007-08-22 파멕사 에이/에스 Ｇｄｆ-8 활성을 하향-조절하는 방법
EP1196617A2 (de) 1999-07-21 2002-04-17 Immunoporation Ltd. Methode zum einführen einer substanz in eine zelle
US7196066B1 (en) * 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US6875748B2 (en) 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
FR2835749B1 (fr) 2002-02-08 2006-04-14 Inst Nat Sante Rech Med Composition pharmaceutique ameliorant le transfert de gene in vivo
EP1432724A4 (de) 2002-02-20 2006-02-01 Sirna Therapeutics Inc Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2535799A1 (en) 2003-08-15 2005-03-03 University Of Florida Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases
EP1671655A4 (de) * 2003-08-29 2009-08-12 Anges Mg Inc Gentherapie für hauterkrankungen mit nadelfreier spritze
EP2395112B1 (de) 2003-12-31 2017-02-15 The Penn State Research Foundation Verfahren zur Vorhersage und Überwindung des Widerstands auf eine Chemotherapie bei Eierstockkrebs und zur Vorhersage des Kolonkrebsvorkommens
JP2005335054A (ja) * 2004-04-27 2005-12-08 Japan Science & Technology Agency 金属ナノワイヤー及びその製造方法
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP2298896A1 (de) 2004-06-22 2011-03-23 The Board of Trustees of the University of Illinois Verfahren zur Inhibierung von Tumorzellwachstum mit FOXM1 siRNS
CA2587950C (en) * 2004-12-01 2014-02-11 Wlt Distributors Inc. Needle-free injector
EP1973946B1 (de) 2006-01-20 2015-03-25 Cell Signaling Technology, Inc. Translokation und mutations-ros-kinase bei menschlichem nicht-kleinzelligem lungenkrebs
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
HUE035732T2 (en) 2006-04-14 2018-05-28 Cell Signaling Technology Inc Gene defects and mutant ALK kinase in human solid tumors
CA2658550C (en) 2006-07-21 2018-06-19 Silence Therapeutics Ag Means for inhibiting the expression of protein kinase 3
US8188214B2 (en) 2007-02-28 2012-05-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
EP2157982B1 (de) 2007-05-04 2014-12-17 Marina Biotech, Inc. Aminosäurelipide und ihre verwendungen
EP3741851A1 (de) 2007-10-18 2020-11-25 Cell Signaling Technology, Inc. Translokation und mutante ros-kinase in humanem nichtkleinzelligem lungenkarzinom
AU2009236270B2 (en) 2008-04-15 2014-06-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for delivering inhibitory oligonucleotides
JP2011521649A (ja) 2008-05-30 2011-07-28 イェール ユニバーシティー 遺伝子発現を改変するための標的化オリゴヌクレオチド組成物
EP2902013A1 (de) 2008-10-16 2015-08-05 Marina Biotech, Inc. Verfahren und Zusammensetzungen zur liposomalen und effizienten Abgabe von Gen-Silencing-Therapeutika
ES2637174T3 (es) 2009-02-12 2017-10-11 Cell Signaling Technology, Inc. Expresión de ROS mutante en el cáncer de hígado humano
JP2012523225A (ja) 2009-04-10 2012-10-04 アソシアシオン・アンスティテュ・ドゥ・ミオロジー 疾患の処置のためのトリシクロ−ｄｎａアンチセンスオリゴヌクレオチド、組成物及び方法
US8710209B2 (en) 2009-12-09 2014-04-29 Nitto Denko Corporation Modulation of HSP47 expression
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139842A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
WO2011146938A1 (en) 2010-05-21 2011-11-24 NanoOncology, Inc. Reagents and methods for treating cancer
US9045755B2 (en) 2010-06-24 2015-06-02 Quark Pharmaceuticals, Inc. Double stranded RNA compounds to RhoA and use thereof
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
EP2609198B8 (de) 2010-08-24 2018-03-28 Sirna Therapeutics, Inc. Einsträngige rnai-mittel mit einem internen nukleinsäurefreien spacer
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
AU2011323508B2 (en) 2010-11-01 2017-04-27 Peptimed, Inc. Compositions of a peptide targeting system for treating cancer
JP6000287B2 (ja) 2011-03-03 2016-09-28 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 肺疾患および損傷を治療するための組成物および方法
DE102011018499A1 (de) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
EP2581448B1 (de) 2011-10-13 2015-01-28 Association Institut de Myologie Tricyclo-phosphorothioat-DNA
KR20140111673A (ko) 2012-01-12 2014-09-19 쿠아크 파마수티칼스 인코퍼레이티드 청력 및 균형 장애를 치료하기 위한 조합요법
PL2838998T3 (pl) 2012-04-18 2018-04-30 Cell Signaling Technology, Inc. EGFR i ROS1 w nowotworze
EP3453762B1 (de) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Sina-zusammensetzungen
ES2704855T3 (es) 2012-09-12 2019-03-20 Quark Pharmaceuticals Inc Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas
US9932578B2 (en) 2012-09-12 2018-04-03 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to P53 and methods of use thereof
US9884886B2 (en) 2012-12-06 2018-02-06 Merck Sharp & Dohme Disulfide masked prodrug compositions and methods
WO2015020960A1 (en) 2013-08-09 2015-02-12 Novartis Ag Novel lncrna polynucleotides
AU2015307186A1 (en) 2014-08-27 2017-04-13 Peptimed, Inc. Anti-tumor compositions and methods
US20190255143A1 (en) 2016-04-18 2019-08-22 The Trustees Of Columbia University In The City Of New York Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash)
WO2022149550A1 (ja) * 2021-01-05 2022-07-14 株式会社ダイセル 注入器

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1026253B2 (de) * 1989-03-21 2012-12-19 Vical Incorporated Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
EP0695186A1 (de) * 1993-04-28 1996-02-07 Ribozyme Pharmaceuticals, Inc. Verabreichung von nukleinsäuren an das auge
EP0800403A2 (de) * 1994-12-30 1997-10-15 Chiron Corporation Nichttraumatische erteilung von genbeförderungsmitteln
US5766901A (en) * 1995-05-04 1998-06-16 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for delivering a nucleotide into cell nuclei
EP0832269A1 (de) * 1995-06-07 1998-04-01 Baylor College Of Medicine Nukleinsäure transporter zur abgabe von nukleinsäure in zellen

Also Published As

Publication number Publication date
JP2003528024A (ja) 2003-09-24
AU1922999A (en) 1999-07-05
EP1038016A2 (de) 2000-09-27
WO1999031262A3 (en) 1999-09-10
WO1999031262A2 (en) 1999-06-24

Similar Documents

Publication Publication Date Title
CA2315256A1 (en) Needle-free injection of formulated nucleic acid molecules
CN110974954B (zh) 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
US7491537B2 (en) Nucleic acid formulations for gene delivery and methods of use
AU2001241958A1 (en) Improved poloxamer and poloxamine compositions for nucleic acid delivery
Combadière et al. Particle-based vaccines for transcutaneous vaccination
Dileo et al. Gene transfer to subdermal tissues via a new gene gun design
US20020102729A1 (en) Formulations for electroporation
Somvanshi et al. Peptide-based DNA delivery system
Fang et al. Applications and challenges of biomaterial mediated mRNA delivery
Chamarthy et al. A cationic peptide consists of ornithine and histidine repeats augments gene transfer in dendritic cells
Manthorpe et al. Plasmid vaccines and therapeutics: from design to applications
CN111603553A (zh) 一种靶向免疫系统治疗肿瘤的dna药物及其应用
WO2001008709A1 (en) Sonoporation of tumors
US20240189414A1 (en) Engineered heartland virus mrna vaccine
Lin et al. An Overview of Nanoparticle-Based Delivery Platforms for Vaccines
Yoshikawa et al. Fusogenic liposomes and their suitability for gene delivery
Teng Yap et al. Navigating the horizon of mRNA vaccines: Tracing their evolution, ensuring safety, and unveiling therapeutic potential.
Singh et al. The Junction of Biomaterials and Gene Therapy–Current Strategies and Future Directions
Sullivan Non-Viral Gene Therapy
Xin et al. mRNA-Based Cancer Therapy and Challenges
JP2003528816A (ja) ヒトおよび動物の病原体のゲノム由来の構築物に基づいたｄｎａワクチン
Ericson et al. 399. Homogeneous Reducible Polypeptides for Nucleic Acid Delivery
Volc-Platzer et al. Nonviral Gene Transfer into the Skin
MacLaughlin et al. Device-mediated gene delivery: a review
Warnier et al. 994. Subcellular Localisation of pDNA in Mouse Liver after an Hydrodynamic Injection

Legal Events

Date Code Title Description
FZDE Dead